1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. DermBiont Acquires SeylanMED

M&A Deal Summary

DermBiont Acquires SeylanMED

On October 21, 2020, DermBiont acquired life science company SeylanMED

Acquisition Highlights
  • This is DermBiont’s 1st transaction in the Life Science sector.
  • This is DermBiont’s 1st transaction in the United States.

M&A Deal Summary
Date 2020-10-21
Target SeylanMED
Sector Life Science
Buyer(s) DermBiont
Deal Type Add-on Acquisition

Target

SeylanMED

United States
SeylanMED, Inc. is a provider in the development of a topical Akt inhibitor as a first in class treatment for seborrheic keratosis. The company’s lead drug candidate (SM-020) is the first molecularly targeted approach for the treatment of this disease.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

DermBiont

Boston, Massachusetts, United States
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

DermBiont, Inc. is a precision dermatology company developing targeted topical therapeutics that treat, cure, and prevent skin diseases by addressing their root cause, beginning with biotherapeutics repairing a dysbiosis of the microbiome and targeted small molecule therapeutics with well-defined mechanisms of action. DermBiont was established in 2017 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal